WO2016206662A1 - Ibrutinib hemisulphate - Google Patents

Ibrutinib hemisulphate Download PDF

Info

Publication number
WO2016206662A1
WO2016206662A1 PCT/CZ2016/000072 CZ2016000072W WO2016206662A1 WO 2016206662 A1 WO2016206662 A1 WO 2016206662A1 CZ 2016000072 W CZ2016000072 W CZ 2016000072W WO 2016206662 A1 WO2016206662 A1 WO 2016206662A1
Authority
WO
WIPO (PCT)
Prior art keywords
ibrutinib
ibmtinib
sulphuric acid
hemisulphate
preparation
Prior art date
Application number
PCT/CZ2016/000072
Other languages
English (en)
French (fr)
Inventor
Pavel ZVATORA
Ondrej Dammer
Lukas KREJCIK
Josef Beranek
Jakub Hert
Original Assignee
Zentiva, K.S.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zentiva, K.S. filed Critical Zentiva, K.S.
Publication of WO2016206662A1 publication Critical patent/WO2016206662A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Definitions

  • the invention relates to a novel solid form of l-[(3i?)-3-[4-amino-3-(4-phenoxyphenyl)-lH- pyrazolo[3,4-d]pyrimidin-l-yl] iperidin-l-yl]prop-2-en-l-one of formula (I),
  • ibrutinib (CAS no. 936563-96-1) ,belongs to the group of kinase inhibitors that can be used for the treatment of lymphomas.
  • Imbruvica Ibrutinib was approved by The Food and Drug Administration (FDA) for the treatment of centrocytic lymphoma.
  • the patent WO2013/184572 deals, besides preparation methods, with the pharmaceutical composition of crystalline and solvated forms of ibrutinib for oral administration and mentions pharmaceutically acceptable salts of this drug without any further description or example of production thereof.
  • Further use of ibrutinib for the treatment of cancer, inflammatory and autoimmune diseases, together with a description of pharmaceutical compositions mentioning its pharmaceutically acceptable salts without further description or example of production thereof is mentioned in the patent WO2014/004707.
  • the solubility of the crystalline free base of ibrutinib in water is very low, even if aqueous solutions with different pH are used. It is clear that novel solid forms of this active pharmaceutical ingredient are needed for the preparation of dosage forms with higher solubility and bioavailability.
  • the invention provides a novel crystalline solid form of ibrutinib in the form of a pharmaceutically acceptable salt with sulphuric acid and methods of its preparation.
  • This salt is prepared by a reaction of ibrutinib in the free base form (formula I) with sulphuric acid in a suitable solvent or mixtures of solvents.
  • the prepared novel crystalline solid form has suitable physical-chemical characteristics for use in the pharmaceutical industry and formulation of new dosage forms.
  • the salt of ibrutinib with sulphuric acid is in the solid phase and in crystalline form; in the DSC record it exhibits the melting point of approximately 121°C.
  • the ibrutinib sulphate is ibrutinib hemisulphate exhibiting the following characteristic diffraction peaks with the use of CuKct radiation: 4.18; 7.96; 14.51; 17.69; and 21.2 ⁇ 0.2° 2-theta.
  • the molar ratio of ibrutinib : sulphuric acid is in the range of 10:1 to 1:3, preferably 2:1.
  • Salts of pharmaceutically active substances generally have higher solubility and bioavailability values than their corresponding basic forms.
  • This invention provides a salt of ibrutinib in a crystalline solid phase.
  • the invention consists in a novel solid form of ibrutinib with sulphuric acid that can be prepared in a crystalline form in adequate yields with high chemical purity.
  • the prepared novel solid form of ibrutinib may have various internal arrangements (polymorphism) with different physical-chemical properties depending on the conditions of its preparation. Therefore, the invention relates to a crystalline or amorphous form of ibrutinib sulphate in any ratio.
  • This novel solid form is suitable for preparation of ibrutinib with high chemical and optical purity.
  • the preparation of the novel form of ibrutinib (formula (I)) is based on a reaction of the free base of ibrutinib with sulphuric acid.
  • the reaction is conducted in a suitable solvent, which can be ketones, esters, ethers, amides, nitriles or organic acids, alcohols, aliphatic and aromatic hydrocarbons, chlorinated hydrocarbons, water or mixtures thereof. Aliphatic C1-C4 alcohols, esters or their mixtures are preferred.
  • the most commonly used solvents are acetone, ethanol, isopropanol, acetonitrile, tetrahydrofuran or mixtures thereof.
  • the final product is typically precipitated or crystallized at temperatures in the range of - 30°C to the boiling point of the solvent.
  • the crystalline form of ibrutinib hemisulphate (according to Example 2) is characterized by the reflections presented in Table 1.
  • Table 1 includes reflections whose relative intensity value is higher than 1 percent.
  • the characteristic diffraction peaks of ibrutinib hemisulphate according to this invention are: 4.18; 7.96; 14.51; 17.69; and 21.2 ⁇ 0.2° 2-theta.
  • An example of the X-ray powder pattern is shown in Figure 1.
  • the melting point of the crystalline form of ibrutinib hemisulphate, prepared according to Example 2, is 121°C (DSC).
  • ibrutinib sulphate prepared according to Example 2 is shown in Fig. 2.
  • the molar ratio of ibrutinib: sulphuric acid can be in the range of 10:1 to 1:3, preferably 2:1.
  • a 10mm mask and a 1/4° fixed anti- dispersion slit were used.
  • the irradiated area of the sample is 10 mm, programmable divergence slits were used.
  • ATR (Ge - single reflection) infrared spectra of the powder samples were measured with an infrared spectrometer (Nicolet Nexus, Thermo, USA) equipped with a DTGS KBr detector, in the measurement range of 600-4000 cm “1 and the spectral resolution of 4.0 cm “1 .
  • the data were obtained at 64 spectrum accumulations.
  • the OMNIC 6.2 software was used to process the spectra.
  • the record of the novel solid form of ibrutinib hemisulphate was measured using a Discovery DSC device made by TA Instruments.
  • the sample charge in a standard Al pot 40 was between 4-5 and 5 mg and the heating rate was 5°C/min.
  • As the carrier gas 5.0 N 2 was used at the flow of 50 ml/min.
  • Example 1 The free base of ibrutinib was prepared according to the procedure mentioned in the patent (WO2008/039218).
  • Example 2 Preparation of ibrutinib hemisulphate l-[(3i?)-3-[4-Amino-3-(4-phenoxyphenyl)- 1 H-pyrazolo[3,4-d]pyrimidin- 1 -yl]piperidin- 1- yl]prop-2-en-l-one (Ibrutinib) in the amount of 2.124 g (4.82-10 "3 mol) was dissolved in 110 ml of acetone. 0.134 ml (2.41 -10 "3 mol) of sulphuric acid (96 %) was added to this solution. After 30 min, the originally clear solution turned into a white suspension. The obtained suspension was further stirred at the room temperature for 2 hours.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PCT/CZ2016/000072 2015-06-26 2016-06-27 Ibrutinib hemisulphate WO2016206662A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CZ2015-442A CZ2015442A3 (cs) 2015-06-26 2015-06-26 Ibrutinib hemisulfát
CZPV2015-442 2015-06-26

Publications (1)

Publication Number Publication Date
WO2016206662A1 true WO2016206662A1 (en) 2016-12-29

Family

ID=56507367

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CZ2016/000072 WO2016206662A1 (en) 2015-06-26 2016-06-27 Ibrutinib hemisulphate

Country Status (2)

Country Link
CZ (1) CZ2015442A3 (cs)
WO (1) WO2016206662A1 (cs)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3501609A1 (en) 2017-12-08 2019-06-26 Zentiva K.S. Pharmaceutical compositions comprising ibrutinib
CN110317203A (zh) * 2019-07-08 2019-10-11 浙江工业大学 一种依鲁替尼和羧酸的共无定型物及其制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008039218A2 (en) * 2006-09-22 2008-04-03 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
WO2013184572A1 (en) * 2012-06-04 2013-12-12 Pharmacyclics, Inc. Crystalline forms of a bruton's tyrosine kinase inhibitor
WO2016050422A1 (en) * 2014-10-01 2016-04-07 Ratiopharm Gmbh Acid addition salt of ibrutinib

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008039218A2 (en) * 2006-09-22 2008-04-03 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
WO2013184572A1 (en) * 2012-06-04 2013-12-12 Pharmacyclics, Inc. Crystalline forms of a bruton's tyrosine kinase inhibitor
WO2016050422A1 (en) * 2014-10-01 2016-04-07 Ratiopharm Gmbh Acid addition salt of ibrutinib

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3501609A1 (en) 2017-12-08 2019-06-26 Zentiva K.S. Pharmaceutical compositions comprising ibrutinib
CN110317203A (zh) * 2019-07-08 2019-10-11 浙江工业大学 一种依鲁替尼和羧酸的共无定型物及其制备方法
CN110317203B (zh) * 2019-07-08 2022-05-13 浙江工业大学 一种依鲁替尼和羧酸的共无定型物及其制备方法

Also Published As

Publication number Publication date
CZ2015442A3 (cs) 2017-01-04

Similar Documents

Publication Publication Date Title
EP2411394B1 (en) Useful pharmaceutical salts of 7-[(3r, 4r)-3-hydroxy-4-hydroxymethyl-pyrrolidin-1-ylmethyl]-3,5-dihydro-pyrrolo[3,2-d]pyrimidin-4-one
EP3256474B1 (en) Ibrutinib sulphate salt
WO2017008773A1 (en) Crystalline forms of obeticholic acid
WO2017174044A1 (en) Solid forms of ibrutinib
EP2791141B1 (en) Tofacitinib mono-tartrate salt
EP3243824A1 (en) Solid forms of ibrutinib free base
WO2016192692A1 (en) Solid forms of tenofovir alafenamide
CN113840604A (zh) Jak2抑制剂的结晶形式
WO2016127963A1 (en) Solid forms of palbociclib salts
US20100190982A1 (en) Process for the preparation of lamivudine form i
WO2016206662A1 (en) Ibrutinib hemisulphate
WO2018046028A1 (en) Solid forms of eluxadoline
WO2016058564A1 (en) Salts of bedaquiline
WO2017186197A1 (en) Salts of lenvatinib
US20150216851A1 (en) Polymorphs of Cocrystals of p-Coumaric Acid:Nicotinamide
EP3063151B1 (en) A stable polymorph of the salt of (2r)-4-oxo-4-[3-(trifiuoromethyl)-5,6- dihydro[l,2,4]triazolo[4,3-a]pyrazin-7(8h)-yl]-l-(2,4,54rifluorophenyl)butan-2-amine with l-tartaric acid
WO2017016529A1 (en) Solid forms of ceritinib free base
CA2964198C (en) Solid forms of nilotinib hydrochloride
EP3031808A1 (en) Salt of idelalisib
CN108727381B (zh) 一种alk酪氨酸激酶抑制剂的盐及其制备方法
KR20200134928A (ko) 발사르탄/사쿠비트릴 3소듐염 수화물의 결정형 및 그 제조방법
WO2016198031A1 (en) A salt of bedaquiline with citric acid
WO2016127962A1 (en) An amorphous solid form of suvorexant with sulphuric acid
KR20210125298A (ko) 테노포비어 알라펜아미드 헤미타르트레이트의 신규한 제조방법
WO2016192691A1 (en) Solid forms of daclatasvir

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16741525

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 16741525

Country of ref document: EP

Kind code of ref document: A1